The Association Between Medication Adherence and Drug-Related Problems (DRPs) with Clinical Outcomes of Diabetes Patients at Public Health Center in Salatiga

https://doi.org/10.22146/jmpf.104444

Anita Kumala Hati(1), Nanang Munif Yasin(2*), Susi Ari Kristina(3)

(1) *) Doctoral Program in Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta *) Pharmacy Study Program, Faculty of Health, Universitas Ngudi Waluyo, Semarang
(2) Department of Pharmacology & Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(3) Department of Pharmaceutics, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Background: Diabetes mellitus (DM) is a disease whose clinical condition can be controlled. The clinical outcomes of DM patients are an important parameter for successful treatment and are influenced by many factors.

Objectives: This study aimed to analyze the relationship between medication compliance and drug-related problems (DRPs) with the clinical outcomes of diabetes patients at three Primary Health centers in Salatiga.

Methods: An observational study method was adopted with prospective data collection from the medical records and medication compliance observation of type 2 diabetes mellitus (T2DM) patients, in October 2023–April 2024. DRP analysis was based on categories Cipolle, 2012, and medication compliance was measured using the pill count method. Data analysis was conducted using the Spearman test to assess the correlation between medication adherence and HbA1c levels, as well as the occurrence of DRP.

Results: A total of 40 subjects participated in this study, with the largest gender being female (72.5%), and hypertension was the most common comorbid condition (55%). The highest compliance rate in patients was 40% and DRP events were detected in 107 cases. The difference in patient HbA1c levels at baseline and the 3rd month showed a significant difference, and 67.5% experienced an increase. Furthermore, there was a strong relationship between compliance and HbA1c achievement (sig = 0.003, r = 0.452), as well as between the incidence of DRP and HbA1c achievement (sig = 0.000, r = 0.644).

Conclusion: Compliance and DRPs influenced the HbA1c levels of T2DM patients in PROLANIS across three Public Health Centres in Salatiga.


Keywords


Compliance; Drug Therapy Problems; HbA1c; Fasting Blood Glucose

Full Text:

PDF


References

  1. Juster-Switlyk K, Smith A. Updates in diabetic peripheral neuropathy. F1000Res. 2016 Apr 25;5:F1000 Faculty Rev-738. doi: F1000Research. 2016;5(0):1-7. doi:https://doi.org/10.12688/f1000research.7898.1
  2. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication Adherence: Truth and Consequences. Am J Med Sci. 2016;351(4):387-399. doi:10.1016/j.amjms.2016.01.010
  3. Kementerian Kesehatan RI. Laporan Riset Kesehatan Dasar (RISKESDAS) 2018. Published online 2019:124-140.
  4. Krska J, Morecroft CW, Rowe PH, Poole H. Measuring the impact of long-term medicines use from the patient perspective. Int J Clin Pharm. 2014;36(4):675-678. doi:10.1007/s11096-014-9970-5
  5. Alfian SD, Sukandar H, Lestari K, Abdulah R. Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study. Diabetes Ther. 2016;7(4):755-764. doi:10.1007/s13300-016-0203-x
  6. Rahmawati DA, Widayanti, MPH., Apt., Ph.D. AW, Kristina SA. Measurement of Medication Adherence Behavior in Type 2 Diabetes Mellitus Patients Using Probabilistic Medication Adherence Scale (ProMAS). J Manaj DAN PELAYANAN Farm (Journal Manag Pharm Pract. 2023;13(3). doi:10.22146/jmpf.84431
  7. Ratnasari PMD, Yani KLPA, Arini HD. ANALYSIS BETWEEN THE NUMBER OF ANTIHYPERTENSIVE WITH MEDICATION ADHERENCE IN END STAGE RENAL DISEASE. J Farm Sains dan Prakt. Published online April 29, 2022:78-89. doi:10.31603/pharmacy.v8i1.5611
  8. Widayanti AW, Norris P, Heydon S, Green JA. Medicine taking behaviours of people with type 2 diabetes in Indonesia: a qualitative study. Int J Clin Pharm. 2020;42(1):31-39. doi:10.1007/s11096-019-00933-0
  9. Alfian S, Sukandar H, Arisanti N AR. Complementary and Alternative Medicine Use Decreases Adherence to Prescribed Medication in Diabetes Patients. Ann Trop Med Public Heal. 2016;9(3):174. doi:https://doi.org/10.1016/j.jams.2018.10.002
  10. Strand L, Cipolle R, Morley P, Frakes M. The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience. Curr Pharm Des. 2004;10(31):3987-4001. doi:10.2174/1381612043382576
  11. 26 MM. 2021 A, 26 14(1):36. Apr, Nigussie A 14(1):36. doi: 10.1186/s40545-021-00312-z. Adem F Abdela J Edessa D Hagos B. Drug-related problems and associated factors in Ethiopia: a systematic review and meta-analysis. J Pharm Policy Pr. 2021;14(36):1-24. doi:https://doi.org/10.1186/s40545-021-00312-z
  12. Singh H, Kumar BN, Sinha T, Dulhani N. The incidence and nature of drug-related hospital admission: A 6-month observational study in a tertiary health care hospital. J Pharmacol Pharmacother. 2011;2(1):17-20. doi:10.4103/0976-500X.77095
  13. Shiomi M, Kurobuchi M, Tanaka Y, Takada T, Otori K. Pill Counting in the Determination of Factors Affecting Medication Adherence in Patients with Type 2 Diabetes: A Retrospective Observational Study. Diabetes Ther. 2021;12(7):1993-2005. doi:10.1007/s13300-021-01091-1
  14. Cipolle, R. J., Strand, L. M., & Morley PC. Pharmaceutical Care Practice: Thepatient Centered Approach to Medication Management. 3rd ed. McGraw-Hill,Health Professions Division; 2012.
  15. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016;37(3):278-316. doi:10.1210/er.2015-1137
  16. Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of Gender in Diabetes Mellitus and Its Complication. Int J Mol Sci. 2022;23(16):8850. doi:10.3390/ijms23168850
  17. Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66(6):986-1002. doi:10.1007/s00125-023-05891-x
  18. Rivera LA, Lebenbaum M, Rosella LC. The influence of socioeconomic status on future risk for developing Type 2 diabetes in the Canadian population between 2011 and 2022: differential associations by sex. Int J Equity Health. 2015;14(1):101. doi:10.1186/s12939-015-0245-0
  19. Kautzky-Willer A, Dorner T, Jensby A, Rieder A. Women show a closer association between educational level and hypertension or diabetes mellitus than males: a secondary analysis from the Austrian HIS. BMC Public Health. 2012;12(1):392. doi:10.1186/1471-2458-12-392
  20. LeWine HE. Taking aim at belly fat. Harvard Health Publishing. Published 2024. Accessed July 31, 2024. https://www.health.harvard.edu/newsletter_article/taking-aim-at-belly-fat
  21. Goswami B, Reang T, Sarkar S, Sengupta S, Bhattacharjee B. Role of body visceral fat in hypertension and dyslipidemia among the diabetic and nondiabetic ethnic population of Tripura—A comparative study. J Fam Med Prim Care. 2020;9(6):2885. doi:10.4103/jfmpc.jfmpc_187_20
  22. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin Expression From Human Adipose Tissue. Diabetes. 2003;52(7):1779-1785. doi:10.2337/diabetes.52.7.1779
  23. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137-2142. doi:10.1016/j.biochi.2012.06.008
  24. Lee B, Shao J. Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2014;15(2):149-156. doi:10.1007/s11154-013-9283-3
  25. Zhao Y, Atun R, Oldenburg B, et al. Physical multimorbidity, health service use, and catastrophic health expenditure by socioeconomic groups in China: an analysis of population-based panel data. Lancet Glob Heal. 2020;8(6):e840-e849. doi:10.1016/S2214-109X(20)30127-3
  26. Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. eClinicalMedicine. 2023;57:101860. doi:10.1016/j.eclinm.2023.101860
  27. Gazzaz ZJ, Iftikhar R, Jameel T, Baig M, Murad MA. Association of Dyslipidemia and Comorbidities with Risk Factors Among Diabetic Patients: A Retrospective Analysis. Diabetes, Metab Syndr Obes Targets Ther. 2020;Volume 13:935-941. doi:10.2147/DMSO.S235546
  28. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2
  29. World Health Organization. Medication Safety in Polypharmacy. Published online 2019:39. https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf
  30. Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. Aging Clin Exp Res. 2022;34(9):1969-1983. doi:10.1007/s40520-022-02165-1
  31. McCracken R, McCormack J, McGregor MJ, Wong ST, Garrison S. Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross-sectional study of nursing home patients in British Columbia, Canada. BMJ Open. 2017;7(8):e017430. doi:10.1136/bmjopen-2017-017430
  32. Kabue S, Liu V, Dyer W, Raebel M, Nichols G, Schmittdiel J. Identifying Common Predictors of Multiple Adverse Outcomes Among Elderly Adults With Type-2 Diabetes. Med Care. 2019;57(9):702-709. doi:10.1097/MLR.0000000000001159
  33. Noale M, Veronese N, Cavallo Perin P, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016;53(2):323-330. doi:10.1007/s00592-015-0790-4
  34. AL‐Musawe L, Torre C, Guerreiro JP, et al. Polypharmacy, potentially serious clinically relevant drug‐drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacol Res Perspect. 2020;8(4). doi:10.1002/prp2.621
  35. Yang Y, Lin M, Wang C, et al. Geriatric syndromes and quality of life in older adults with diabetes. Geriatr Gerontol Int. 2019;19(6):518-524. doi:10.1111/ggi.13654
  36. Forbes A, Murrells T, Sinclair AJ. Examining factors associated with excess mortality in older people (age ≥ 70 years) with diabetes – a 10‐year cohort study of older people with and without diabetes. Diabet Med. 2017;34(3):387-395. doi:10.1111/dme.13132
  37. Dobrică EC, Găman MA, Cozma MA, Bratu O, Pantea Stoian A, Diaconu C. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina (B Aires). 2019;55(8):436. doi:10.3390/medicina55080436
  38. Rätsep A, Oja I, Kalda R, Lember M. Family doctors’ assessment of patient- and health care system-related factors contributing to non-adherence to diabetes mellitus guidelines. Prim Care Diabetes. 2007;1(2):93-97. doi:10.1016/j.pcd.2007.03.002
  39. Zhang Q, Zhao C, Davies MJ, Radican L, Seck T. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am J Manag Care. 2011;17(11):746-752. doi:22084894
  40. PERKENI. Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia. PB. PERKENI; 2021. www.ginasthma.org.
  41. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033
  42. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
  43. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug Therapies for Diabetes. Int J Mol Sci. 2023;24(24):17147. doi:10.3390/ijms242417147
  44. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
  45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
  46. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019;140(9):739-750. doi:10.1161/CIRCULATIONAHA.119.042007
  47. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389
  48. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493. doi:10.2337/dci19-0066
  49. Awang Jihadi MH, Yuda A, Sukorini AI, Hermansyah A, Shafqat N, Tan CS ML. Drug-related problems in hospitalized patients with type 2 diabetes mellitus: A systematic review. Explor Res Clin Soc Pharm. 2023;12(100348):2667-2766. doi:https://doi.org/10.1016/j.rcsop.2023.100348
  50. Rusdiana, Savira M, Amelia R. The Effect of Diabetes Self-Management Education on Hba1c Level and Fasting Blood Sugar in Type 2 Diabetes Mellitus Patients in Primary Health Care in Binjai City of North Sumatera, Indonesia. Open Access Maced J Med Sci. 2018;6(4):715-718. doi:10.3889/oamjms.2018.169
  51. Haas L, Maryniuk M, Beck J, et al. National standards for diabetes self-management education and support. Diabetes Care. 2014;37 Suppl 1(July 2012):1630-1637. doi:10.2337/dc14-s144
  52. Besemah NA, Sartika RAD SR. Effect of Pharmacist Intervention on Medication Adherence and Clinical Outcomes of Type 2 Diabetes Mellitus Outpatients in Primary Healthcare in Indonesia. J Res Pharm Pr. 2021;9(4):186-195. doi:10.4103/jrpp.JRPP_20_59
  53. Suprapti B, Izzah Z, Anjani AG, Andarsari MR, Nilamsari WP, Nugroho CW. Prevalence of medication adherence and glycemic control among patients with type 2 diabetes and influencing factors: A cross-sectional study. Glob Epidemiol. 2023;5:100113. doi:10.1016/j.gloepi.2023.100113
  54. Katadi S, Andayani TM, Endarti D. The Correlation of Treatment Adherence with Clinical Outcome and Quality of Life in Patients with Type 2 Diabetes. J Manaj DAN PELAYANAN Farm (Journal Manag Pharm Pract. 2019;9(1):19. doi:10.22146/jmpf.42927
  55. Saraiva EMS, Coelho JLG, dos Santos Figueiredo FW, do Souto RP. Medication non-adherence in patients with type 2 diabetes mellitus with full access to medicines. J Diabetes Metab Disord. 2020;19(2):1105-1113. doi:10.1007/s40200-020-00612-2
  56. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi:10.1136/bmj.38875.675486.55
  57. Arpey NC, Gaglioti AH, Rosenbaum ME. How Socioeconomic Status Affects Patient Perceptions of Health Care: A Qualitative Study. J Prim Care Community Health. 2017;8(3):169-175. doi:10.1177/2150131917697439
  58. Egede LE, Gebregziabher M, Dismuke CE, et al. Medication Nonadherence in Diabetes. Diabetes Care. 2012;35(12):2533-2539. doi:10.2337/dc12-0572
  59. Nelson LA, Wallston KA, Kripalani S, LeStourgeon LM, Williamson SE, Mayberry LS. Assessing barriers to diabetes medication adherence using the Information-Motivation-Behavioral skills model. Diabetes Res Clin Pract. 2018;142:374-384. doi:10.1016/j.diabres.2018.05.046
  60. Al-Sahouri A, Merrell J, Snelgrove S. Barriers to good glycemic control levels and adherence to diabetes management plan in adults with Type-2 diabetes in Jordan: a literature review. Patient Prefer Adherence. 2019;Volume 13:675-693. doi:10.2147/PPA.S198828
  61. Kementerian Kesehatan RI. Formularium Nasional 2023. Published online 2023:57.
  62. Bathari ACR, Rahmawati F, Sari IP. Hubungan Drug Related Problems (DRPs) Obat Antidiabetika terhadap Ketercapaian Kendali Glikemik pada Pasien Rawat Inap Diabetes Melitus Tipe 2 dengan Komplikasi Nyeri Neuropati. J Manaj DAN PELAYANAN Farm (Journal Manag Pharm Pract. 2021;10(4). doi:10.22146/jmpf.57829
  63. Astuti SY, Ihsan M, Rahmawati F. Hubungan antara Drug-Related Problems dan Lama Rawat Inap pada Pasien dengan Diabetes Tipe 2. J Manaj DAN PELAYANAN Farm (Journal Manag Pharm Pract. 2020;10(2):77. doi:10.22146/jmpf.43576
  64. Doggrell SA, Warot S. The association between the measurement of adherence to anti-diabetes medicine and the HbA1c. Int J Clin Pharm. 2014;36(3):488-497. doi:10.1007/s11096-014-9929-6
  65. Ahmad NS, Islahudin F, Paraidathathu T. Factors associated with good glycemic control among patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(5):563-569. doi:10.1111/jdi.12175
  66. Polonsky W, Henry R. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;Volume 10:1299-1307. doi:10.2147/PPA.S106821
  67. Alqarni AM, Alrahbeni T, Al Qarni A, Al Qarni HM. Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia – a cross-sectional survey. Patient Prefer Adherence. 2018;Volume 13:63-71. doi:10.2147/PPA.S176355
  68. Scarton L, Nelson T, Yao Y, DeVaughan-Circles A, Legaspi AB, Donahoo WT, Segal R, Goins RT, Manson SM WD. Association of Medication Adherence With HbA1c Control Among American Indian Adults With Type 2 Diabetes Using Tribal Health Services. Diabetes Care. 2023;46(6):1245-1251. doi:https://doi.org/10.2337/dc22-1885
  69. Destasya G. Hubungan Kejadian Drug Related Problems (DRPs) Obat Antidiabetik Dengan Ketercapaian Kendali Glikemik Pada Pasien Rawat Inap Diabetes Melitus Tipe 2 Komplikasi Hipertensi Di Rumah Sakit UNS Tahun 2022. 2022.



DOI: https://doi.org/10.22146/jmpf.104444

Article Metrics

Abstract views : 217 | views : 55

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats